About Realm Therapeutics
Realm Therapeutics is a Healthcare company based in Malvern (United States) founded in 1997, and was acquired by ESSA Pharma in May 2019. Immunomodulatory formulations for the treatment of eye and skin inflammation. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Diversified. Its legal entity is Realm Therapeutics plc. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Realm Therapeutics (formerly known as PuriCore) is utilising its immunomodulatory formulations to develop small molecule therapies for inflammatory diseases with application in dermatology and ophthalmology. Its topical products in development include PR013, a topical solution for allergic conjunctivitis (eye inflammation) (Phase 1); PR022, a topical gel for atopic dermatitis (Phase 1).
- Headquarters Malvern, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website realmtx.com
- Social LinkedIn
- Acquired by ESSA Pharma (May 2019)
- Legal Name Realm Therapeutics Plc
- Latest Funding Round$20.5M (USD), Post-IPO
Oct 2017
- InvestorsESSA Pharma
& 7 more
- Acquired byESSA Pharma
(May 2019)
Funding Insights of Realm Therapeutics
- Total Rounds 6
- Last Round Post-IPO — $20.5M
- First Round $20M
(Oct 2007)
- Investors Count 7
All 6 funding rounds of Realm Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $20.5M | Post-IPO | – | – | – |
| Sep 2017 | $26.1M | Post-IPO | – | – | |
| Apr 2010 | $1.8M | Debt – Venture | – | – | |
| Aug 2009 | $2.1M | Debt – Venture | – | – | |
| Oct 2008 | $9.74M | Debt – Venture | – | – | – |
| Oct 2007 | $20M | Debt – Venture | – | – |
8 investors in total: 8 institutional.
Investors in Realm Therapeutics
Realm Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include ESSA Pharma, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Private equity investments are managed from a USA base. | bbh.com | Beijing, China | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Polar Capital is recognized as a specialist active fund manager. | polarcapital.co.uk | London, United Kingdom | ||
Fulton Bank is operated as a financial institution offering banking services. | 1988 | myrepublicbank.com | Philadelphia, United States | |
Small molecule drugs for cancer treatment are developed. | 2009 | essapharma.com | Vancouver, Canada |
Investor details for Realm Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Realm Therapeutics
1 people are tracked at Realm Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Vadim Panichev | Director Technology Applicaions | Leadership |
Complete people profiles for Realm Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Realm Therapeutics
5 dated milestones of Realm Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Realm Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.0M.
- Funding Latest funding round, Post-IPO, of $20.5M.
- Exit Acquired by ESSA Pharma.
Competitors of Realm Therapeutics
Realm Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Realm Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Realm Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Realm Therapeutics
Complete news archive for Realm Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Realm Therapeutics
Realm Therapeutics was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Realm Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Realm Therapeutics (formerly known as PuriCore) is utilising its immunomodulatory formulations to develop small molecule therapies for inflammatory diseases with application in dermatology and ophthalmology. Its topical products in development include PR013, a topical solution for allergic conjunctivitis (eye inflammation) (Phase 1); PR022, a topical gel for atopic dermatitis (Phase 1).
Realm Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Realm Therapeutics has 8 investors. Key investors include ESSA Pharma, Orbimed, RA Capital, Fulton Bank, and Abingworth.
Realm Therapeutics operates through Realm Therapeutics Plc.
Yes. Realm Therapeutics was acquired by ESSA Pharma in May 2019.